[Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children--a 12-year follow-up].
OBJECTIVE
To evaluate protective efficacy of a plasma-derived hepatitis B vaccine during 12 years after vaccination.


METHODS
A 12-year follow-up of 350 children who participated a randomized, double blind, placebo-controlled trial in 1982.


RESULTS
During the 12 years after vaccination, more vaccinated children had anti-HBs of 10 S/N ratios or more than did the controls. At the 12 years 46.1% of the vaccinated and 33.9% of the controls retained anti-HBs levels of S/N ratios > or = 10 (P < 0.05). However, at 12 years median S/N ratio of anti-HBs of the vaccinated children with detectable anti-HBs was lower than that of the controls (15 vs 36, P < 0.0001). Protective efficacy against HBsAg carriage status at 5-10 years after vaccination varied from 83% to 100%. At 12 years, 14 chronic HBsAg carriers were identified among the controls, whereas only 1 case was noted in the vaccinated group (7.6% vs 0.6%, P < 0.01), account for an efficacy of 92%.


CONCLUSIONS
Protective efficacy against chronic HBsAg carriage was satisfactory at 12 years after vaccination. No evidence was showed to support a booster of hepatitis B vaccine at this time.
Liao
S
S
Institute of Basic Medical Sciences, CAMS and PUMC, Beijing 100005.
Li
R
R
Li
H
H
Yang
J
J
Zeng
X
X
D002675:Child, Preschool; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007223:Infant; D014611:Vaccination
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines